Jiangsu Yahong Pharmaceutical Technology Co., Ltd
Initial public offering and listing on the science and Innovation Board
Online roadshow announcement
Sponsor (lead underwriter): Citic Securities Company Limited(600030)
Jiangsu Yahong Pharmaceutical Technology Co., Ltd. (hereinafter referred to as “the issuer”) made an initial public offering of RMB common shares (A shares) and was listed on the science and Innovation Board (hereinafter referred to as “this offering”) ）The application was examined and approved by the stock listing committee of the science and Innovation Board of Shanghai Stock Exchange on September 23, 2021, and has been approved for registration in the document of CSRC zjxk [2021] No. 3797.
This offering is conducted by a combination of directional placement to strategic investors (hereinafter referred to as “strategic placement”), offline inquiry placement to qualified investors (hereinafter referred to as “offline issuance”), and online pricing issuance to social public investors holding non restricted A-Shares and non restricted depositary receipts market value in Shanghai market (hereinafter referred to as “online issuance”).
Citic Securities Company Limited(600030) (hereinafter referred to as ” Citic Securities Company Limited(600030) ” or “sponsor (lead underwriter)”) serves as the sponsor (lead underwriter) of this offering. The issuer and the sponsor (lead underwriter) will directly determine the issue price through offline preliminary inquiry, and offline cumulative bidding will not be conducted.
It is proposed to issue 110 million new shares, accounting for about 19.30% of the total share capital of the issuer after the issuance. The initial number of strategic placements issued in this offering is 5.5 million shares, accounting for 5.00% of the number of shares issued in this offering. The difference between the final number of strategic placements and the initial number of strategic placements will be first transferred back to offline issuance. Before the launch of the callback mechanism, the initial number of shares issued offline was 83.6 million, accounting for about 80.00% of the number issued after deducting the initial strategic placement, and the initial number of shares issued online was 20.9 million, accounting for about 20.00% of the number issued after deducting the initial strategic placement. The total quantity of final offline and online issuance is the total quantity of this issuance minus the final strategic placement quantity. The final online and offline issuance quantity will be determined according to the callback situation.
In order to facilitate investors to understand the relevant information of the issuer and the relevant arrangements of this offering, the issuer and the sponsor (lead underwriter) of this offering will hold an online roadshow on this offering. Please pay attention to it.
1. Online roadshow time: 9:00-12:00 a.m. on December 24, 2021 (t-1);
2. Online roadshow website:
Shanghai Securities roadshow Center: http://roadshow.sseinfo.com.
China Securities Network: http://roadshow.cn.stock.com.
3. Participants: major members of the board of directors and management of the issuer and relevant personnel of the sponsor (lead underwriter).
The full text of the letter of intent of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. for initial public offering and listing on the science and innovation board and relevant materials can be queried on the website of Shanghai Stock Exchange (www.sse. Com.. CN). Please pay attention to the majority of investors.
Issuer: Jiangsu Yahong Pharmaceutical Technology Co., Ltd
Sponsor (lead underwriter): Citic Securities Company Limited(600030)
December 23, 2021
(there is no text on this page, which is the seal page of the online roadshow announcement of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. on initial public offering and listing on the science and Innovation Board)
Issuer: Jiangsu Yahong Pharmaceutical Technology Co., Ltd. (this page has no text and is the seal page of the online roadshow announcement of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. on initial public offering and listing on the science and Innovation Board)
Sponsor (lead underwriter): Citic Securities Company Limited(600030) mm / DD / yy
